Last update: Nov. 3, 2020
Minimal risk for breastfeeding and infant.
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). Indicated in rheumatic diseases, gout, dysmenorrhea, adnexitis, and post-traumatic or post-operative pain and inflammation.
Oral administration in two to three daily doses. It can also be administered intramuscularly or intravenously.
Its pharmacokinetic data (high percentage of protein binding and short half-life) explain the zero or miniscule transfer into breastmilk observed:
The drug is excreted in milk in insignificant or undetectable quantities (AEMPS 2017, Sandoz 2017, Hale 2017 p.277, Hutchinson 2013, Worthington 2013, ABM 2012, Østensen 2007, Sioufi 1982).
No adverse effects have been detected in breastfed babies whose mothers were taking it (Yefet 2017, Davanzo 2014, Hutchinson 2013, Hirose 1996).
For all these reasons it is considered compatible with breastfeeding (Yefet 2017, Davanzo 2014, Hutchinson 2013, Amir 2011, Lee 1993, Brooks 1990, Goldsmith 1989, Needs 1985).
Most non-steroidal anti-inflammatories can increase jaundice, so it is preferable to avoid them during the neonatal period in mothers of jaundiced infants. (Janssen 2000).
The small dose and poor plasma uptake of most topical dermatological or ophthalmological preparations make it very unlikely that significant amounts will pass into breast milk.
Ophthalmic or dermatological use is completely compatible with breastfeeding.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.